JP2009538331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009538331A5 JP2009538331A5 JP2009512244A JP2009512244A JP2009538331A5 JP 2009538331 A5 JP2009538331 A5 JP 2009538331A5 JP 2009512244 A JP2009512244 A JP 2009512244A JP 2009512244 A JP2009512244 A JP 2009512244A JP 2009538331 A5 JP2009538331 A5 JP 2009538331A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- disorder
- antidepressant
- way
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 benzothiadiazide Chemical compound 0.000 claims 18
- 239000000935 antidepressant agent Substances 0.000 claims 15
- 229940005513 antidepressants Drugs 0.000 claims 15
- 239000005557 antagonist Substances 0.000 claims 14
- 230000001430 anti-depressive effect Effects 0.000 claims 12
- 206010041250 Social phobia Diseases 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 8
- 229960003162 iloperidone Drugs 0.000 claims 7
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims 7
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 6
- 229960003299 ketamine Drugs 0.000 claims 6
- 208000024714 major depressive disease Diseases 0.000 claims 6
- 239000002207 metabolite Substances 0.000 claims 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 6
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 5
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 5
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 5
- 208000029364 generalized anxiety disease Diseases 0.000 claims 5
- 208000019906 panic disease Diseases 0.000 claims 5
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 5
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 4
- NEWKHUASLBMWRE-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine Chemical compound CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 NEWKHUASLBMWRE-UHFFFAOYSA-N 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims 4
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 4
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims 4
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 230000000561 anti-psychotic effect Effects 0.000 claims 4
- 229950006137 dexfosfoserine Drugs 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 229960003987 melatonin Drugs 0.000 claims 4
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims 4
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims 4
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 4
- NRBNGHCYDWUVLC-UHFFFAOYSA-N mtep Chemical compound S1C(C)=NC(C#CC=2C=NC=CC=2)=C1 NRBNGHCYDWUVLC-UHFFFAOYSA-N 0.000 claims 4
- 229960002296 paroxetine Drugs 0.000 claims 4
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims 4
- 229960003770 reboxetine Drugs 0.000 claims 4
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims 4
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 4
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 4
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 4
- 201000009916 Postpartum depression Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- FERIKTBTNCSGJS-OBLUMXEWSA-N (1r,2s)-4-aminocyclopentane-1,2,4-tricarboxylic acid Chemical compound OC(=O)C1(N)C[C@H](C(O)=O)[C@H](C(O)=O)C1 FERIKTBTNCSGJS-OBLUMXEWSA-N 0.000 claims 2
- QLOOWOVVZLBYHU-VIFPVBQESA-N (2s)-1-(7-ethylfuro[2,3-g]indazol-1-yl)propan-2-amine Chemical compound O1C(CC)=CC2=C1C=CC1=C2N(C[C@H](C)N)N=C1 QLOOWOVVZLBYHU-VIFPVBQESA-N 0.000 claims 2
- SBBYBXSFWOLDDG-JLTOFOAXSA-N (2s)-n-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-n-methylpiperazine-1-carboxamide Chemical compound C1([C@H]2CNCCN2C(=O)N(C)[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=CC=C(F)C=C1C SBBYBXSFWOLDDG-JLTOFOAXSA-N 0.000 claims 2
- NJXZWIIMWNEOGJ-WEWKHQNJSA-N (2s,4r)-1-[(3r)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxoindol-3-yl]-4-hydroxy-n,n-dimethylpyrrolidine-2-carboxamide Chemical compound COC1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2[C@@](N2[C@@H](C[C@@H](O)C2)C(=O)N(C)C)(C=2C(=CC=CC=2)OC)C1=O NJXZWIIMWNEOGJ-WEWKHQNJSA-N 0.000 claims 2
- KJEAKWPQCIAVGR-MERQFXBCSA-N (3s)-3-[(5-methoxy-2,3-dihydro-1h-inden-4-yl)oxy]pyrrolidine;hydrochloride Chemical compound Cl.COC1=CC=C2CCCC2=C1O[C@H]1CCNC1 KJEAKWPQCIAVGR-MERQFXBCSA-N 0.000 claims 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 2
- CEPHEXXZGQBXGT-XZTIXWOLSA-N (e)-but-2-enedioic acid;(2s)-1-(6-chloro-5-fluoroindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.FC1=C(Cl)C=C2N(C[C@@H](N)C)C=CC2=C1 CEPHEXXZGQBXGT-XZTIXWOLSA-N 0.000 claims 2
- XIGAHNVCEFUYOV-BTJKTKAUSA-N (z)-but-2-enedioic acid;n-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-n-pyridin-2-ylcyclohexanecarboxamide Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC=CC=C1N1CCN(CCN(C(=O)C2CCCCC2)C=2N=CC=CC=2)CC1 XIGAHNVCEFUYOV-BTJKTKAUSA-N 0.000 claims 2
- HMXQIFUGFZEJEO-UHFFFAOYSA-N 1,2-dihydropyrrol-3-one Chemical compound O=C1CNC=C1 HMXQIFUGFZEJEO-UHFFFAOYSA-N 0.000 claims 2
- DXNOFPQQCQAJFH-MRXNPFEDSA-N 1-(2-iodophenyl)-n-[3-[[(2r)-pyrrolidin-2-yl]methyl]-1h-indol-5-yl]methanesulfonamide Chemical compound IC1=CC=CC=C1CS(=O)(=O)NC1=CC=C(NC=C2C[C@@H]3NCCC3)C2=C1 DXNOFPQQCQAJFH-MRXNPFEDSA-N 0.000 claims 2
- YXTROGRGRSPWKL-UHFFFAOYSA-N 1-benzoylpiperidine Chemical compound C=1C=CC=CC=1C(=O)N1CCCCC1 YXTROGRGRSPWKL-UHFFFAOYSA-N 0.000 claims 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 2
- LJUNPHMOGNFFOS-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-6-yl(piperidin-1-yl)methanone Chemical compound C=1C=C2OCCOC2=CC=1C(=O)N1CCCCC1 LJUNPHMOGNFFOS-UHFFFAOYSA-N 0.000 claims 2
- 125000004565 2,3-dihydrobenzofuran-4-yl group Chemical group O1CCC2=C1C=CC=C2* 0.000 claims 2
- NZDIZJGEDFARSV-UHFFFAOYSA-N 2-amino-4-(5-methyl-3-oxo-1,2-oxazol-4-yl)butanoic acid Chemical compound CC=1ONC(=O)C=1CCC(N)C(O)=O NZDIZJGEDFARSV-UHFFFAOYSA-N 0.000 claims 2
- QBBJSFUFEUXTNU-UHFFFAOYSA-N 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-n-pentan-3-ylpyrazolo[1,5-a]pyrimidin-7-amine Chemical compound CC1=NN2C(NC(CC)CC)=CC(C)=NC2=C1C1=CC=C(OC)C=C1C QBBJSFUFEUXTNU-UHFFFAOYSA-N 0.000 claims 2
- JCFULPDIJOVUHP-KSSFIOAISA-N 3-[(1s)-1-[[(2s)-3-[cyclohexylmethyl(hydroxy)phosphoryl]-2-hydroxypropyl]amino]ethyl]benzoic acid Chemical compound C([C@@H](O)CN[C@@H](C)C=1C=C(C=CC=1)C(O)=O)P(O)(=O)CC1CCCCC1 JCFULPDIJOVUHP-KSSFIOAISA-N 0.000 claims 2
- ONNMDRQRSGKZCN-UHFFFAOYSA-N 3-aminopropyl(butyl)phosphinic acid Chemical compound CCCCP(O)(=O)CCCN ONNMDRQRSGKZCN-UHFFFAOYSA-N 0.000 claims 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 claims 2
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 claims 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims 2
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims 2
- GIUZEIJUFOPTMR-UHFFFAOYSA-N 6-chloro-5-methyl-n-[6-(2-methylpyridin-3-yl)oxypyridin-3-yl]-2,3-dihydroindole-1-carboxamide Chemical compound C1=2C=C(Cl)C(C)=CC=2CCN1C(=O)NC(C=N1)=CC=C1OC1=CC=CN=C1C GIUZEIJUFOPTMR-UHFFFAOYSA-N 0.000 claims 2
- PHGWDAICBXUJDU-UHFFFAOYSA-N 8,9-dichloro-1,2,3,4,4a,6-hexahydropyrazino[1,2-a]quinoxalin-5-one Chemical compound N1C(=O)C2CNCCN2C2=C1C=C(Cl)C(Cl)=C2 PHGWDAICBXUJDU-UHFFFAOYSA-N 0.000 claims 2
- MDWRPTOUDPFXKK-UHFFFAOYSA-N 8-(2,4-dichlorophenyl)-n-(1,3-dimethoxypropan-2-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound CC1=NN2C(NC(COC)COC)=NC(C)=NC2=C1C1=CC=C(Cl)C=C1Cl MDWRPTOUDPFXKK-UHFFFAOYSA-N 0.000 claims 2
- 101800001144 Arg-vasopressin Proteins 0.000 claims 2
- 102400000059 Arg-vasopressin Human genes 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 2
- ANDGGVOPIJEHOF-UHFFFAOYSA-N CX-516 Chemical compound C=1C=C2N=CC=NC2=CC=1C(=O)N1CCCCC1 ANDGGVOPIJEHOF-UHFFFAOYSA-N 0.000 claims 2
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 claims 2
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 claims 2
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims 2
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 2
- 229930195711 D-Serine Natural products 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- JFHJGXQFESYQGY-UHFFFAOYSA-N Emicerfont Chemical compound CC1=CC(OC)=CC=C1N1C(N=C(C)C=C2N3N=C(C=C3)N3C(NCC3)=O)=C2CC1 JFHJGXQFESYQGY-UHFFFAOYSA-N 0.000 claims 2
- 208000027534 Emotional disease Diseases 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 229930195714 L-glutamate Natural products 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- OIGHTPDWPMLMGT-UHFFFAOYSA-N LSM-3233 Chemical compound C1CNCC2=CC=CC3=C2N1C1=C3CCCC1 OIGHTPDWPMLMGT-UHFFFAOYSA-N 0.000 claims 2
- 102000029828 Melanin-concentrating hormone receptor Human genes 0.000 claims 2
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 claims 2
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims 2
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims 2
- FJDDSMSDZHURBJ-UHFFFAOYSA-N N-[2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl]acetamide Chemical compound COC1=CC=C2NC(I)=C(CCNC(C)=O)C2=C1 FJDDSMSDZHURBJ-UHFFFAOYSA-N 0.000 claims 2
- OFCLARYYBGKCHN-UHFFFAOYSA-N N-[2-(5-methoxy-2-phenyl-1H-indol-3-yl)ethyl]acetamide Chemical compound CC(=O)NCCC=1C2=CC(OC)=CC=C2NC=1C1=CC=CC=C1 OFCLARYYBGKCHN-UHFFFAOYSA-N 0.000 claims 2
- LUINDDOUWHRIPW-UHFFFAOYSA-N N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)ethyl]acetamide Chemical compound C1=C(Cl)C(OC)=CC2=C1NC=C2CCNC(C)=O LUINDDOUWHRIPW-UHFFFAOYSA-N 0.000 claims 2
- YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 claims 2
- HZZZZODVDSHQRG-UHFFFAOYSA-N N-[5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxopentyl]-2,4-dimethoxyphenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound COC1=CC(OC)=C(C(=O)CCCCN2CCC3(CC2)C(NC(=O)N3)=O)C=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 HZZZZODVDSHQRG-UHFFFAOYSA-N 0.000 claims 2
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 claims 2
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 2
- LBWQSAZEYIZZCE-SNVBAGLBSA-N Pexacerfont Chemical compound CC1=NN2C(N[C@H](C)CC)=NC(C)=NC2=C1C1=CC=C(OC)N=C1C LBWQSAZEYIZZCE-SNVBAGLBSA-N 0.000 claims 2
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 claims 2
- ATQMRMGXINTJHV-UHFFFAOYSA-N SB 224289 Chemical compound C1CN(C)CCC11C2=CC(N(C(=O)C=3C=CC(=CC=3)C=3C(=CC(=CC=3)C=3N=C(C)ON=3)C)CC3)=C3C=C2OC1 ATQMRMGXINTJHV-UHFFFAOYSA-N 0.000 claims 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 claims 2
- 239000000674 adrenergic antagonist Substances 0.000 claims 2
- 229960002629 agomelatine Drugs 0.000 claims 2
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 claims 2
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 claims 2
- 229960000793 aniracetam Drugs 0.000 claims 2
- 239000000164 antipsychotic agent Substances 0.000 claims 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims 2
- 229940049706 benzodiazepine Drugs 0.000 claims 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 2
- 229960001058 bupropion Drugs 0.000 claims 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 2
- BOCUKUHCLICSIY-QJWLJZLASA-N cyclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1[C@H](C=C2)C[C@H]2C1 BOCUKUHCLICSIY-QJWLJZLASA-N 0.000 claims 2
- 229960003176 cyclothiazide Drugs 0.000 claims 2
- QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002996 emotional effect Effects 0.000 claims 2
- 229960002464 fluoxetine Drugs 0.000 claims 2
- 229960002449 glycine Drugs 0.000 claims 2
- 229960003998 ifenprodil Drugs 0.000 claims 2
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 claims 2
- 229960005417 ketanserin Drugs 0.000 claims 2
- HOQAVGZLYRYHSO-UHFFFAOYSA-N ly-404,187 Chemical compound C1=CC(C(C)CNS(=O)(=O)C(C)C)=CC=C1C1=CC=C(C#N)C=C1 HOQAVGZLYRYHSO-UHFFFAOYSA-N 0.000 claims 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 2
- 229960004640 memantine Drugs 0.000 claims 2
- 229960001785 mirtazapine Drugs 0.000 claims 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 2
- RVIGBTUDFAGRTQ-LLVKDONJSA-N n-[(2r)-8-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl]propanamide Chemical compound C1=CC(OC)=C2C[C@H](NC(=O)CC)CCC2=C1 RVIGBTUDFAGRTQ-LLVKDONJSA-N 0.000 claims 2
- QFAUPDBCVKBKSH-UHFFFAOYSA-N n-[2-(4-thiophen-3-ylphenyl)propyl]propane-2-sulfonamide Chemical compound C1=CC(C(C)CNS(=O)(=O)C(C)C)=CC=C1C1=CSC=C1 QFAUPDBCVKBKSH-UHFFFAOYSA-N 0.000 claims 2
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 claims 2
- 239000002746 neurokinin 2 receptor antagonist Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims 2
- 229960002508 pindolol Drugs 0.000 claims 2
- 229960004526 piracetam Drugs 0.000 claims 2
- 229940035613 prozac Drugs 0.000 claims 2
- 229960001150 ramelteon Drugs 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 229940023942 remeron Drugs 0.000 claims 2
- PGKXDIMONUAMFR-AREMUKBSSA-N saredutant Chemical compound C([C@H](CN(C)C(=O)C=1C=CC=CC=1)C=1C=C(Cl)C(Cl)=CC=1)CN(CC1)CCC1(NC(C)=O)C1=CC=CC=C1 PGKXDIMONUAMFR-AREMUKBSSA-N 0.000 claims 2
- 239000002485 serotonin 2C agonist Substances 0.000 claims 2
- 239000002484 serotonin 2C antagonist Substances 0.000 claims 2
- 229960002073 sertraline Drugs 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 2
- 229960004688 venlafaxine Drugs 0.000 claims 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 2
- 229950007305 vestipitant Drugs 0.000 claims 2
- XOSKJKGKWRIMGV-DGCLKSJQSA-N way-163909 Chemical compound C1NCCN2[C@@H]3CCC[C@@H]3C3=CC=CC1=C32 XOSKJKGKWRIMGV-DGCLKSJQSA-N 0.000 claims 2
- 229940020965 zoloft Drugs 0.000 claims 2
- JSXDLWRIIOHHIC-UHFFFAOYSA-N 1H-cyclopropa[b]chromene-1a-carboxamide Chemical compound C1=CC=C2OC(C3)(C(=O)N)C3=CC2=C1 JSXDLWRIIOHHIC-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010002869 Anxiety symptoms Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010010144 Completed suicide Diseases 0.000 claims 1
- 206010011971 Decreased interest Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- 206010022998 Irritability Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000001431 Psychomotor Agitation Diseases 0.000 claims 1
- 206010038743 Restlessness Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 206010042464 Suicide attempt Diseases 0.000 claims 1
- 208000021017 Weight Gain Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- 208000019017 loss of appetite Diseases 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 235000020830 overeating Nutrition 0.000 claims 1
- 230000002688 persistence Effects 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 239000003727 serotonin 1A antagonist Substances 0.000 claims 1
- 239000004000 serotonin 1B antagonist Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000002618 waking effect Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74786106P | 2006-05-22 | 2006-05-22 | |
| PCT/US2007/069373 WO2007137227A1 (en) | 2006-05-22 | 2007-05-21 | Treatment for depressive disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009538331A JP2009538331A (ja) | 2009-11-05 |
| JP2009538331A5 true JP2009538331A5 (enExample) | 2010-09-02 |
Family
ID=38723631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009512244A Pending JP2009538331A (ja) | 2006-05-22 | 2007-05-21 | 抑うつ障害のための治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090306137A1 (enExample) |
| EP (1) | EP2029136A4 (enExample) |
| JP (1) | JP2009538331A (enExample) |
| KR (1) | KR20090029200A (enExample) |
| AU (1) | AU2007253684A1 (enExample) |
| BR (1) | BRPI0711872A2 (enExample) |
| CA (1) | CA2652416A1 (enExample) |
| MX (1) | MX2008014843A (enExample) |
| RU (1) | RU2008150624A (enExample) |
| WO (1) | WO2007137227A1 (enExample) |
| ZA (1) | ZA200809528B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8362277B2 (en) * | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| US9962368B2 (en) | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| WO2010081115A1 (en) | 2009-01-09 | 2010-07-15 | University Of Texas Southwestern Medical Center | Pro-neurogenic compounds |
| US9162980B2 (en) | 2009-01-09 | 2015-10-20 | Board Of Regents Of The University Of Texas System | Anti-depression compounds |
| MX2012007365A (es) | 2009-12-23 | 2012-08-15 | Lupin Ltd | Composiciones farmaceuticas de liberacion lenta de iloperidona. |
| FR2956031B1 (fr) * | 2010-02-11 | 2012-03-02 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc) |
| CN103415289B (zh) | 2010-07-07 | 2017-04-12 | 得克萨斯州大学系统董事会 | 前神经原性化合物 |
| CN103429223A (zh) * | 2011-01-17 | 2013-12-04 | 武田药品工业株式会社 | 口腔分散片 |
| US8426461B2 (en) | 2011-01-17 | 2013-04-23 | Takeda Pharmaceutical Company Limited | Orally dispersible tablet |
| FR2978916B1 (fr) * | 2011-08-10 | 2013-07-26 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
| RU2465895C1 (ru) * | 2011-09-08 | 2012-11-10 | Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" | Способ лечения депрессивного невроза |
| WO2013054582A1 (en) * | 2011-10-14 | 2013-04-18 | Takeda Pharmaceutical Company Limited | Orally dispersible tablet |
| US20130236573A1 (en) * | 2012-03-12 | 2013-09-12 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| EP2825167B1 (en) | 2012-03-14 | 2018-05-09 | Vanda Pharmaceuticals Inc. | An iloperidone metabolite for use in the treatment of psychiatric disorders |
| EP2841068B8 (en) * | 2012-04-23 | 2019-03-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Crhr1 antagonists for use in the treatment of patients having crh overactivity |
| MX2014014010A (es) | 2012-05-18 | 2015-02-12 | Vanda Pharmaceuticals Inc | Metabolitos de (1r-trans) -n - [[2- (2,3-dihidro-4-benzofuranilo) ciclopropilo] metilo] propanamida. |
| RU2488388C1 (ru) * | 2012-05-24 | 2013-07-27 | Ооо "Валента Интеллект" | Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств |
| GB201210686D0 (en) | 2012-06-15 | 2012-08-01 | Holsboermaschmeyer Neurochemie Gmbh | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
| CA2882826A1 (en) | 2012-08-24 | 2014-02-27 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| UA107653U (uk) | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
| WO2014120936A2 (en) | 2013-01-30 | 2014-08-07 | Pharmorx Therapeutics, Inc. | Treatments for depression and other diseases with a low dose agent |
| PE20200404A1 (es) | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina |
| GB201310782D0 (en) | 2013-06-17 | 2013-07-31 | Max Planck Innovation Gmbh | Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms |
| KR101484405B1 (ko) * | 2013-08-14 | 2015-01-19 | 서울대학교산학협력단 | Ｎｉｎｊｕｒｉｎ１ 결핍 유래의 강박증 예방 또는 치료용 약학적 조성물 |
| EP3068388A4 (en) | 2013-11-11 | 2017-04-12 | Board of Regents of the University of Texas System | Neuroprotective compounds and use thereof |
| WO2015070237A1 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective chemicals and methods for identifying and using same |
| CA3155599A1 (en) | 2014-01-21 | 2015-07-30 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
| RU2571546C1 (ru) * | 2014-07-14 | 2015-12-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации | Способ дифференцированной диагностики и терапии синдрома ночной еды |
| CA2957926A1 (en) | 2014-08-13 | 2016-02-18 | Janssen Pharmaceutica Nv | Method for the treatment of depression |
| KR20170054470A (ko) | 2014-09-15 | 2017-05-17 | 얀센 파마슈티카 엔.브이. | VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법 |
| US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9744239B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| IL275482B1 (en) | 2017-12-22 | 2025-03-01 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| EP3505157B1 (en) | 2017-12-29 | 2021-12-08 | Celon Pharma S.A. | Dry powder ketamine composition for pulmonary administration in treatment-resistant depression |
| MA56226A (fr) | 2018-12-07 | 2022-04-20 | Neurocrine Biosciences Inc | Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale |
| WO2020178653A1 (en) | 2019-03-05 | 2020-09-10 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
| CN118252829A (zh) | 2019-09-27 | 2024-06-28 | 纽罗克里生物科学有限公司 | Crf受体拮抗剂及使用方法 |
| EP4065109A4 (en) | 2019-11-27 | 2023-09-13 | Neurorive Inc | CYCLOSERINE AND LITHIUM COMBINATION THERAPY FOR THE TREATMENT OF DEPRESSION |
| IL295374A (en) * | 2020-02-04 | 2022-10-01 | Mindset Pharma Inc | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4804663A (en) * | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| US5158952A (en) * | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| US5776963A (en) | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
| US5364866A (en) * | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| AU2927392A (en) | 1991-11-01 | 1993-06-07 | National-Standard Company | Age resistant solder coatings |
| MXPA03006003A (es) * | 2001-01-02 | 2005-09-08 | Upjohn Co | Nuevas combinaciones de farmacos. |
| GB0102841D0 (en) * | 2001-02-05 | 2001-03-21 | Novartis Ag | Organic compounds |
| US20020123490A1 (en) * | 2001-03-01 | 2002-09-05 | Pfizer Inc. | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis |
| ATE518845T1 (de) * | 2001-08-31 | 2011-08-15 | Novartis Pharma Gmbh | Optische isomere eines iloperidon-metaboliten |
| CA2463158C (en) | 2001-10-30 | 2013-07-30 | Novartis Ag | Depot formulations of iloperidone and a star polymer |
| SI1458888T1 (sl) | 2001-12-10 | 2011-07-29 | Novartis Ag | Metode zdravljenja psihoze in shizofrenije na osnovi polimorfizmov gena cntf |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| US6831077B2 (en) * | 2002-07-25 | 2004-12-14 | Comprehensive Neuroscience, Inc. | Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation |
| MXPA05000294A (es) * | 2002-07-30 | 2005-08-19 | Peter Migaly | Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas. |
| US20050203130A1 (en) * | 2003-12-02 | 2005-09-15 | Erik Buntinx | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| EP1799865B1 (en) * | 2004-09-30 | 2012-06-06 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
-
2007
- 2007-05-21 BR BRPI0711872-4A patent/BRPI0711872A2/pt not_active IP Right Cessation
- 2007-05-21 US US12/301,675 patent/US20090306137A1/en not_active Abandoned
- 2007-05-21 EP EP07783990A patent/EP2029136A4/en not_active Ceased
- 2007-05-21 CA CA002652416A patent/CA2652416A1/en not_active Abandoned
- 2007-05-21 MX MX2008014843A patent/MX2008014843A/es unknown
- 2007-05-21 RU RU2008150624/14A patent/RU2008150624A/ru not_active Application Discontinuation
- 2007-05-21 WO PCT/US2007/069373 patent/WO2007137227A1/en not_active Ceased
- 2007-05-21 AU AU2007253684A patent/AU2007253684A1/en not_active Abandoned
- 2007-05-21 KR KR1020087029908A patent/KR20090029200A/ko not_active Ceased
- 2007-05-21 JP JP2009512244A patent/JP2009538331A/ja active Pending
-
2008
- 2008-11-07 ZA ZA200809528A patent/ZA200809528B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009538331A5 (enExample) | ||
| RU2008150624A (ru) | Лечение депрессивных расстройств | |
| RU2019143572A (ru) | Композиции для лечения посттравматического стрессового расстройства | |
| Ables et al. | Antidepressants: update on new agents and indications | |
| AU2005302589B2 (en) | Adjunctive therapy for depression | |
| JP2023100904A5 (enExample) | ||
| JP2017509686A5 (enExample) | ||
| JP2013544850A5 (enExample) | ||
| Shelton | Treatment options for refractory depression | |
| RU2011137131A (ru) | Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха | |
| JP2005523334A5 (enExample) | ||
| JP7158425B2 (ja) | Ｎｋ－１アンタゴニスト組成物およびうつ病の処置における使用法 | |
| JP2004527551A (ja) | エナンチオ純粋なエスシタロプラムの使用方法 | |
| JP2007513052A5 (enExample) | ||
| JP2009542819A5 (enExample) | ||
| JP2007513052A (ja) | セロトニン再取り込み阻害剤およびアゴメラチンの併用。 | |
| JP2009542820A5 (enExample) | ||
| JP2002530341A5 (enExample) | ||
| RU2006133263A (ru) | Применение ингибиторов холинэстеразы для лечения сосудистой депрессии | |
| WO2004100939B1 (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
| JP2007513896A5 (enExample) | ||
| Bodkin et al. | Selegiline and other atypical monoamine oxidase inhibitors in depression | |
| RU2009101146A (ru) | Лечение ожирения антагонистами мускаринового рецептора м1 | |
| Namazi et al. | Synergistic Effects of Piperine and Memantine on Reducing the Symptoms of Depression and BDNF Expression in Corticosterone Model of Depression in Amygdala and Hippocampus of Rat Brain | |
| AU2012307535A1 (en) | Combinations comprising a S1P receptor modulator |